Galenika celebrates 80 years of business this year. A pharmaceutical company that bases its perseverance on tradition, knowledge, quality and innovation, has achieved rapid growth and development after privatization and subsequent investments
In the seven years since it became part of the Brazilian NC Group, Galenika produced over 310 million packages of products, and increased sales in Serbia by as much as 84 percent. Investments were made in the construction of 3 new factories as well as modernization and capacity expansion of existing facilities, the product portfolio was significantly increased, and with a strategic partnership with a sister company from Brazil – EMS, Galenika successfully realized the transfer of technology for 13 products from the newer generation of generic drugs.
In the year of its eightieth anniversary, Galenika is preparing for a major innovation in the market in the form of a peptide platform, on which it is working together with its sister company EMS in Brazil. The first drugs for the treatment of obesity and diabetes, based on peptides, have already been registered in Brazil, and sales are expected to begin within two months. We expect the same products to be registered this year in Serbia, the EU and the USA.
“The eightieth anniversary of the Galenika company is a sign of expansion – both of the product portfolio, as well as the continued internationalization of business and continuous innovation. Our peptide platform is a great example and represents a real revolution, both for us here and for our company in Brazil. Being at the top of the pharmaceutical industry of the entire region, as a synonym for health, quality and trust, is a great achievement of the company. We have the expertise and vision for the future and our goal is to lead the further development of the pharmaceutical industry. Innovation and responsibility inspire us and make us determined to continue with exceptional results in the future,” said Ricardo Vian Marques, CEO of Galenika.
In the past 80 years, Galenika has won as many as 103 domestic and international awards in the field of research and development, and continues with constant growth and quality, which is the basis of trust in its brand and products. It has expanded its operations to 30 international markets and as many as four continents. Among the latest achievements is the cooperation with the company that is building the first domestic pharmaceutical factory in Azerbaijan and which has recognized Galenika as a partner with top expertise – the partnership includes the transfer of technology of Galenika’s products, as well as the transfer of knowledge. In addition, Galenika has started its first business activities in Latin American markets and plans dynamic growth in new markets in the EU and MENA region.
Review of the Previous Year’s Results
In 2024, Galenika achieved an increase in sales in Serbia by 11 percent, and in regional markets by as much as 15 percent. It has registered 82 products in Serbia, 166 in the region, and 33 in international markets. The company has as many as 64 brands in the top 3 leadership positions in their categories by market share in Serbia in 2024.
In addition to expanding the product portfolio with newly registered products of the newer generation, during 2024 Galenika also signed exclusive, international agreements on the distribution of products from the Spanish manufacturer – Cantabria Labs and the Austrian – CromaPharma, while a year ago it did the same with the Italian company PharmaLife Research. These partnerships strategically enrich Galenika’s portfolio with modern and effective pharmaceutical products of the highest quality.
The company is dedicated to the continuous professional development of its employees and increases the number of working hours invested in training every year. In addition to employees, Galenika invests significant funds and resources in training partners. Last year, it organized and sponsored almost 100 different professional medical gatherings for more than a thousand healthcare workers from Serbia. On the other hand, in 2024, the accredited training programs of the “Galenika Academy” program had more than 12,000 participants – pharmacists and pharmaceutical technicians, which makes up 80 percent of the pharmacy community, as well as 6,500 other health professionals, which is even a quarter of their total number in Serbia.
***
Pharmaceutical company Galenika was founded in 1945. At the end of 2017, it became part of the NC Group (www.gruponc.net.br), which also includes EMS – the largest pharmaceutical company in Brazil and one of the largest pharmaceutical companies in all of Latin America. With a portfolio of over 330 products, Galenika manufactures generic drugs, dietary supplements, cosmetic products, medical devices and items of general use. The Group’s strategy is the development of Galenika as a modern and flexible company, focused on research and development, which constantly works on improving its products to improve health and quality of life, to the satisfaction of users.